Treatment of cancer with 2-deoxyglucose

Details Treatment of cancer with 2-deoxyglucose Treatment of cancer with 2-deoxyglucose

2005-12-27

2005-12-27

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S024000, C514S025000

Reexamination Certificate

active

06979675

ABSTRACT:
The compound 2-deoxyglucose can be used to treat cancer and to improve patient outcome when administered at a therapeutically effective dose, and, optionally, co-administered with other anti-cancer drugs, or in combination with surgical resection or radiation therapy.

REFERENCES:
patent: 4315001 (1982-02-01), Blough
patent: 5185325 (1993-02-01), Brawn et al.
patent: 5565434 (1996-10-01), Barfknecht et al.
patent: 5591429 (1997-01-01), Wilson et al.
patent: 5643883 (1997-07-01), Marchase et al.
patent: 6218435 (2001-04-01), Henry et al.
patent: 6410029 (2002-06-01), Mukhopadhyay et al.
patent: 6489302 (2002-12-01), Wiessler et al.
patent: 6670330 (2003-12-01), Lampidis et al.
patent: 2002/0035071 (2002-03-01), Pitha et al.
patent: 2002/0077300 (2002-06-01), Khosla et al.
patent: 2003/0072814 (2003-04-01), Maibach et al.
patent: 0565785 (1993-10-01), None
patent: 980100107 (1999-11-01), None
patent: 54-41384 (1979-04-01), None
patent: WO 01/82926 (2001-11-01), None
patent: WO 02/058741 (2002-08-01), None
Kerr et al., abstract entitled “Normal production and increased oxidation of glucose associated with epinephrine defiency in keotoic hypoglycemia”, Pediatric Research, 8:434, 1972.
Woodward et al., “2-desoxy-D-glucose as an inhibitor of anaerobic glycolysis in tumor tissue”, Notes Biochem. Res. Found., Journal of the Franklin Institute, vol. 254, issue 3, pp. 259-60, Sep. 1952.
Wegienka et al., abstract entitled “Use of 2-deoxy-D-glucose to stimulate function of adrenal medulla”, Clinical Res., vol. XIII, No. 1, pp. 134, Jan. 1965.
Reinhold et al., “Antitumoral action of 2-deoxy-D-glucose tetraacelate in human melanoma cells”, Oncol. Rep., vol. 7, pp. 1093-97, 2000.
Malaisse et al., “Cytotoxic action of 2-deoxy-D-glucose tetraacetate in tumoral pancreatic islet cells”, Cancer Lett, 125(1-2), pp. 45-49, Mar. 1998.
Jha et al., Reversibility of inhibition of DNA double strand break repair by 2-deoxy-D-glucose in Ehrlich ascites tumour cells, Int. J. Rad. Bio., vol. 63(4), pp. 459-487, 1993.
Liu et al.,Biochem. Pharmacol., 2002,64:1745-51.
AFT et al.,Br. J. Cancer,2002, 87:805-12.
Chandna et al.,Rad. Res.,2002, 157:516-25.
Mese et al.,Anticancer Res.,2001, 21:1029-33.
Liu et al.,Biochemistry,May 8, 2001, 40: 5542-7.
Yamada et al.,Cancer Chemother. Pharmacol.,1999, 44:59-64.
Dwarakanath et al.,Int. J. Rad. Oncol. Biol. Phys.,1999, 43(5):1125-33.
Belfi et al.,BBRC,1999, 257:361-8.
Kalia,Indian J. Med. Res.,May 1999, 109:182-7.
Haga et al.,Int. J. Cancer,1998, 76:86-90.
Chatterjee et al.,Cancer Res.,Nov. 15, 1997, 57:5112-16.
Kaplan et al.,Cancer Res.,Apr. 15, 1997, 57:1452-9.
Vivi et al.,Breast Cancer Res. Treat.,1997, 43:15-25.
Tomida et al.,Oncogene,1996, 13:2699-2705.
Kraegen et al.,Am. J. Physiol.,1985, 248: E353-E362.
Yun et al.,Oncology Res.,1995, 7(12):583-590.
Halicka et al.,Cancer Res.,Jan. 15, 1995, 55:444-9.
Schaider et al.,J. Cancer Res. Clin. Oncol.,1995, 121(4):203-10.
Griffiths et al.,Int. J. Biochem.,1993, 25(12):1749-55.
Kalia,Indian J. Exp. Biol.,Apr. 1993, 31:312-5.
Haberkorn et al.,J. Nucl. Med.,Nov. 1992, 33(11):1981-7.
Cay et al.,Cancer Res.,Oct. 15, 1992, 52:5794-6.
Kaplan et al.,Cancer Res.,Mar. 15, 1991, 51:1638-44.
Kaplan et al.,Cancer Res.,Feb. 1, 1990, 50:544-51.
Dwarakanath et al.,Indian J. Med. Res.,Jun. 1990, 92:183-8.
Ohtani et al.,Jpn. J. Exp. Med.,Apr. 1990, 60(2):57-65.
Herr et al.,Cancer Res.,Apr. 15, 1988, 48:2061-3.
Jain et al.,Int. J. Radiat. Oncol. Biol. Phys.,May 1985, 11(5):943-50.
Lampidis et al.,Cancer Res.,Feb. 1983, 43:716-20.
Steiner et al.,Cancer Lett.,Jul. 1983, 19(3):333-42.
Sridhar et al.,Br. J. Cancer,1978, 37:141-4.
Myers et al.,BBRC,1975, 63(1):164-71.
Bessel et al.,Biochem. J.,1972, 128:199-204.
Bicz et al.,Arch. Immunol. Ther. Exp.,1967, 15(1):112-4.
AFT et al.,Proceed. AACR,Mar. 2003, 44: Abstract No 123.
Richardson et al.,Proceed. AACR,Mar. 2003, 44: Abstract No. 6239.
Wan et al.,FASEB J.,Apr. 2003, 17(9):1133-4 (Web version).
Dwarakanath et al.,Indian J. Exp. Biol.,Sep. 1999, 37(9):865-70.
Latz et al.,Strahlenther. Onkol.,1993, 169(7):405-11.
Harrigan et al.,Int. J. Hyperthermia,1992, 8(4):475-83.
Karczmar et al.,Cancer Res.,Jan. 1, 1992, 52:71-6.
Juling-Pohlit et al.,Strahlenther. Onkol.,1990,166(1):6-9.
Saydjari et al.,Invest. New Drugs,1989, 7:131-8.
Mack et al.,Eur J Cancer Clin. Oncol.,Sep. 1988, 24(9):1433-7.
Kern et al.,Surgery,Aug. 1987, 102(2):380-5.
Gridley et al.,Int. J. Rad. Oncol. Biol. Phys.,Mar. 1985, 11:567-74.
Dills et al.,J. Nutr.,1984, 114(11):2097-106.
Tannock et al.,Cancer Res.,Mar. 1983, 43(3):980-3.
Bernal et al.,Science,Oct. 14, 1983, 222:169-72.
Purohit,Int. J. Rad. Oncol. Biol. Phys.,Mar.-Apr. 1982, 8(3-4):495-9.
Laszlo et al.,JNCI,Feb. 1960, 24 (2):267-279.
Ball et al.,Cancer Res.,Apr. 1957, 17(3):235-9.
Sokoloff et al.,AMA Arch. Path.,Jun. 1955, 59(6):729-32.
Abbink et al.,J. Card. Pharml.,2001, 37:94-100.
Adler et al.,Neuropsychopharmacology,2000, 22(5):545-50.
George et al.,Alcohol Clin. Exp. Res.,May/Jun. 1994, 18(3):685-91.
Breier et al.,Arch. Gen. Psychiatry,Jul. 1993, 50:541-50.
Breier et al.,Psychopharmacology,1991, 104:479-84.
Breier,Biol. Psychiatry,1989, 26:438-62.
Fagius et al.,Am. J. Physiol.,1989, 256(6.1):E714-20.
Hansen et al.,Ped. Res.,1984, 18(5):490-5.
Hansen et al.,Metabolism,Oct. 1983, 32(10):960-70.
Kerr et al.,Metabolism,Oct., 1983, 32(10):951-9.
Thompson et al.,Metabolism,Oct. 1981, 30(10):1015-20.
Thompson et al.,Am. J. Physiol.,Sep. 1980, 239(3):291-295.
Thompson et al.,Science,Dec. 9, 1977, 198:1065-8.
Woolf et al.,J. Clin. Endocr. Metab.,1977, 45(3):377-83.
Weber et al.,J. Surg. Res.,1975, 18:491-5.
Burckhardt et al.,Digestion,1975, 12:1-8.
Gough et al.,Gut,1975, 16:171-6.
Brodows et al.,J. Clin. Invest.,Aug. 1973, 52:1841-4.
Sizonenko et al.,Ped. Res.,1973, 7:983-93.
Peytremann et al.,Europ. J. Clin. Invest.,1972, 2:432-8.
Freinkel et al.,NEJM,Oct. 26, 1972, 287(17):841-5.
Lipman et al.,Metabolism,1970, 19(11):980-7.
Thomas et al.,Gut,1968, 9:125-8.
Grasso et al.,J. Clin. Endocr.,1968, 28:535-42.
Wegienka et al.,Metabolism,Mar. 1967, 16(3):245-56.
Wegienka et al.,J. Clin. Endocr.,Jan. 1966, 26:37-45.
Duke et al.,Lancet,Oct. 30, 1965, 871-6
Harlan et al.,J. Clin. Endrocrinol. Metab.,Jan. 1963, 23:41-9.
Laszlo et al.,J. Clin. Invest.,Jan. 1961, 40:171-6.
Landau et al.,JNCI,Sep. 1958, 21(3):485-494.
Mohanti et al.,Int. J. Rad. Oncol. Biol. Phys.,1996, 35(1):103-11.
Blough et al., JAMA, Jun. 29, 1979, 241(26): 2798-2801.
Song et al.,Cancer Res.,Dec. 1978, 38: 4499-4503.
Song et al.,Br. J. Cancer,1978, Suppl. III:136-140.
Song et al.,JNCI,Sep. 1976, 57(3): 603-605.
Clavo et al.,J. Nuc. Med.,Sep. 1995, 36(9):1625-1632.
Mesmer et al.,Biochem. Mol. Biol. Int.,Oct. 1996, 40(2): 217-33.
Shen et al., May 1987,Proc. Natl. Acad. Sci. USA 84:3278-3282.
Colofiore et al., Oct. 1982,Cancer Res. 42:3934-3940.
Hughes et al., 1989,Cancer Res. 49:4452-4454.
Mese et al., 2001,Anticancer Res. 21(2A): 1029-33.
Teicher et al., Jan. 1981,Cancer Res. 41:73-81.
Mazurek et al., 1997,J. Bioener. Biomem.29(4): 315-330.
Jensen et al., 1992,Cancer Chemother. Pharmacol. 31:46-52.
Kim et al., Apr. 14, 1978,Science 200:206-207.
Lam et al., 1999,Anti-cancer Drugs 10:171-178.
Bessell et al., 1972,Biochem J. 128:199-204.
Bessell et al., 1973,Eur. J. Cancer 9:463-470.

Affiliated with

Also associated with

Rating

Treatment of cancer with 2-deoxyglucose does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of cancer with 2-deoxyglucose, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancer with 2-deoxyglucose will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3492237